CAFCIT Drug Patent Profile
✉ Email this page to a colleague
When do Cafcit patents expire, and what generic alternatives are available?
Cafcit is a drug marketed by Hikma and is included in one NDA.
The generic ingredient in CAFCIT is caffeine citrate. There are eleven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the caffeine citrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cafcit
A generic version of CAFCIT was approved as caffeine citrate by EXELA PHARMA SCIENCE on September 21st, 2006.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CAFCIT?
- What are the global sales for CAFCIT?
- What is Average Wholesale Price for CAFCIT?
Summary for CAFCIT
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 34 |
| Clinical Trials: | 11 |
| Patent Applications: | 319 |
| Drug Prices: | Drug price information for CAFCIT |
| DailyMed Link: | CAFCIT at DailyMed |
Recent Clinical Trials for CAFCIT
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Arkansas | Phase 1 |
| Thrasher Research Fund | Phase 1 |
| University of North Carolina, Chapel Hill | Phase 1 |
Pharmacology for CAFCIT
| Drug Class | Central Nervous System Stimulant Methylxanthine |
| Physiological Effect | Central Nervous System Stimulation |
US Patents and Regulatory Information for CAFCIT
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hikma | CAFCIT | caffeine citrate | SOLUTION;INTRAVENOUS | 020793-001 | Sep 21, 1999 | AP | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| Hikma | CAFCIT | caffeine citrate | SOLUTION;ORAL | 020793-002 | Apr 12, 2000 | DISCN | Yes | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for CAFCIT
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Gennisium Pharma | Gencebok | caffeine citrate | EMEA/H/C/005435 Treatment of primary apnoea of premature newborns. |
Authorised | no | no | no | 2020-08-19 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
